... long haul, though. Gilead's gains over the past 20 years rival those of Express Scripts. It currently dominates the HIV/AIDS drug market with products including Atripla, Stribild, Truvada, and Viread. The bad news is that Gilead faces the expiration ...
http://www.fool.com/investing/general/2013/08/17/3-great-buy-and-hold-health-care-stocks.aspx
http://www.fool.com/investing/general/2013/08/17/3-great-buy-and-hold-health-care-stocks.aspx
No comments:
Post a Comment